The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1231
March 27, 2006
View Complete Issue         Table of Contents 2019 
Clobetasol Propionate (Clobex) Spray for Psoriasis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Clobetasol Propionate (Clobex) Spray for Psoriasis
March 27, 2006 (Issue: 1231)
The FDA has approved a new spray formulation of the super-high-potency corticosteroid clobetasol propionate 0.05% (Clobex - Galderma) for treatment of moderate to severe plaque psoriasis in adults. Clobetasol propionate is also available as a cream,...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Clobetasol Propionate (Clobex) Spray for Psoriasis
Article code: 1231b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.